International Journal of Cancer,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 13, 2025
Abstract
The
use
of
Immune
checkpoint
inhibitors
(ICIs)
as
monotherapy
for
patients
with
hepatocellular
carcinoma
(HCC)
has
been
associated
an
increased
risk
hyperprogressive
disease
(HPD),
the
occurrence
which
carries
a
poor
prognosis.
However,
it
is
unknown
whether
contemporary
frontline
treatment
combination
atezolizumab
and
bevacizumab
causes
significant
HPD.
This
study
conducted
secondary
analysis
patient‐level
data
from
IMbrave150
randomized
controlled
trial
plus
versus
sorafenib
HCC.
Multiple
established
definitions
early
progression
failure
applicable
to
clinical
trials
were
evaluated,
including
Response
Evaluation
Criteria
in
Solid
Tumours
(RECIST)
HPD,
HPD
based
on
percent
change
sum
longest
diameter
(SLD
HPD),
(TF
fast
(FP).
incidence
these
measures
was
compared
between
arms.
factors
prognosis
TF
evaluated.
RECIST
significantly
lower
than
treatment—odds
ratio
HPD:
0.29
(95%
CI
0.01
0.82),
0.30
(0.17,
0.54).
similarly
prognosis,
irrespective
arm.
High
blood
alpha‐fetoprotein
neutrophil‐to‐lymphocyte
both
For
all
progression/treatment
failure,
either
sorafenib,
or
there
no
differences.
Atezolizumab
unlikely
cause
Journal of Clinical Medicine,
Год журнала:
2023,
Номер
12(13), С. 4301 - 4301
Опубликована: Июнь 27, 2023
Checkpoint
proteins
are
an
integral
part
of
the
immune
system
and
used
by
tumor
cells
to
evade
response,
which
helps
them
grow
uncontrollably.
By
blocking
these
proteins,
checkpoint
inhibitors
can
restore
capability
attack
cancer
stop
their
growth.
These
findings
backed
adequate
clinical
trial
data
presently,
several
FDA-approved
exist
in
market
for
treating
various
types
cancers,
including
melanoma,
hepatocellular,
endometrial,
lung,
kidney
others.
Their
mode
action
is
inhibition
targeting
CTLA-4,
PD-1,
PD-L1,
etc.
They
be
alone
as
well
amalgamation
with
other
treatments,
like
surgery,
radiation
or
chemotherapy.
Since
drugs
target
only
specific
side
effects
reduced
comparison
traditional
chemotherapy
drugs,
but
may
still
cause
a
few
affects
fatigue,
skin
rashes,
fever.
In
rare
cases,
known
have
caused
more
serious
effects,
such
cardiotoxicity,
inflammation
intestines
lungs.
Herein,
we
provide
overview
role
biomarkers,
immune-related
adverse
outcomes
studies
treatment
present
some
future
perspectives.
Bioconjugate Chemistry,
Год журнала:
2023,
Номер
34(11), С. 1951 - 2000
Опубликована: Окт. 11, 2023
Antibody–drug
conjugates
(ADCs)
are
targeted
immunoconjugate
constructs
that
integrate
the
potency
of
cytotoxic
drugs
with
selectivity
monoclonal
antibodies,
minimizing
damage
to
healthy
cells
and
reducing
systemic
toxicity.
Their
design
allows
for
higher
doses
drug
be
administered,
potentially
increasing
efficacy.
They
currently
among
most
promising
classes
in
oncology,
efforts
expand
their
application
nononcological
indications
combination
therapies.
Here
we
provide
a
detailed
overview
recent
advances
ADC
research
consider
future
directions
challenges
promoting
this
platform
widespread
therapeutic
use.
We
examine
data
from
CAS
Content
Collection,
largest
human-curated
collection
published
scientific
information,
analyze
publication
landscape
reveal
exploration
trends
documents
insights
into
area.
also
discuss
evolution
key
concepts
field,
major
technologies,
development
pipelines
company
focuses,
disease
targets,
stages,
investment
trends.
A
comprehensive
concept
map
has
been
created
based
on
Collection.
hope
report
can
serve
as
useful
resource
understanding
current
state
knowledge
field
ADCs
remaining
fulfill
potential.
Advanced Drug Delivery Reviews,
Год журнала:
2024,
Номер
209, С. 115306 - 115306
Опубликована: Апрель 16, 2024
Cancer
immunotherapy
represents
a
revolutionary
strategy,
leveraging
the
patient's
immune
system
to
inhibit
tumor
growth
and
alleviate
immunosuppressive
effects
of
microenvironment
(TME).
The
recent
emergence
checkpoint
blockade
(ICB)
therapies,
particularly
following
first
approval
cytotoxic
T-lymphocyte-associated
protein
4
(CTLA-4)
inhibitors
like
ipilimumab,
has
led
significant
in
cancer
immunotherapy.
extensive
explorations
on
diverse
antibodies
have
broadened
therapeutic
scope
for
various
malignancies.
However,
clinical
response
these
antibody-based
ICB
therapies
remains
limited,
with
less
than
15%
responsiveness
notable
adverse
some
patients.
This
review
introduces
emerging
strategies
overcome
current
limitations
mainly
focusing
development
small
interfering
ribonucleic
acid
(siRNA)-based
innovative
delivery
systems.
We
firstly
highlight
target
genes
siRNA-based
incorporating
silencing
multiple
boost
anti-tumor
responses.
Subsequently,
we
discuss
improvements
siRNA
systems,
enhanced
by
nanocarriers,
aimed
at
overcoming
siRNA's
challenges
such
as
vulnerability
enzymatic
degradation,
inadequate
pharmacokinetics,
possible
unintended
interactions.
Additionally,
presents
combination
that
integrate
chemotherapy,
phototherapy,
stimulatory
checkpoints,
antibodies,
vaccines.
important
point
is
when
used
therapy,
synergistic
effect
traditional
strengthened,
improving
host
surveillance
outcomes.
Conclusively,
insights
into
effective
immunotherapeutic
based
RNA
interference
(RNAi)
technology
utilizing
nanocarriers
novel
approach
Frontiers in Cell and Developmental Biology,
Год журнала:
2025,
Номер
12
Опубликована: Янв. 13, 2025
Consolidation
with
PD-1/PD-L1-based
immune
checkpoint
blockade
after
concurrent
platinum-based
chemo-radiotherapy
has
become
the
new
standard
of
care
for
advanced
stage
III
unresectable
non-small
cell
lung
cancer
(NSCLC)
patients.
In
order
to
further
improve
therapy
outcomes,
innovative
combinatorial
treatment
strategies
aim
target
additional
immunosuppressive
barriers
in
tumor
microenvironment
such
as
CD73/adenosine
pathway.
CD73
and
adenosine
are
known
crucial
endogenous
regulators
homeostasis
inflammation,
but
also
contribute
an
microenvironment.
Furthermore,
pathway
can
limit
immune-activating
effects
cytotoxic
therapies
by
degrading
pro-inflammatory
danger
molecule
ATP,
which
is
released
into
normal
tissue
upon
therapy-induced
damage.
Thus,
while
targeting
may
enhance
efficacy
radio-immunotherapies
mitigating
escape
improving
immune-mediated
killing,
it
raises
concerns
about
increased
immune-related
adverse
events
(irAEs)
tissue.
fact,
combined
bear
risk
irAEs
lungs,
pharmacologic
inhibition
overwhelming
or
overlapping
pulmonary
toxicity
thereby
outcome.
This
review
explores
how
therapeutic
interventions
dynamics
could
radiation-induced
activation
radio-immunotherapies,
whilst
potentially
driving
lung.
We
specifically
investigate
interactions
between
radiotherapy
radiation
pneumonitis.
Additionally,
we
compare
incidence
(radiation)
pneumonitis
reported
relevant
trials
determine
if
there
clinical
setting.
By
understanding
these
dynamics,
inform
future
optimizing
radio-immunotherapy
regimens,
ensuring
effective
control
preserving
integrity
patient
quality
life.
Journal of Nanobiotechnology,
Год журнала:
2023,
Номер
21(1)
Опубликована: Сен. 21, 2023
Abstract
Immune
checkpoint
(ICP)
molecules
expressed
on
tumor
cells
can
suppress
immune
responses
against
tumors.
ICP
therapy
promotes
anti-tumor
by
targeting
inhibitory
and
stimulatory
pathways
of
like
T
dendritic
(DC).
The
investigation
into
the
combination
therapies
through
novel
inhibitors
(ICIs)
has
been
limited
due
to
immune-related
adverse
events
(irAEs),
low
response
rate,
lack
optimal
strategy
for
combinatorial
cancer
immunotherapy
(IMT).
Nanoparticles
(NPs)
have
emerged
as
powerful
tools
promote
multidisciplinary
cooperation.
feasibility
efficacy
targeted
delivery
ICIs
using
NPs
overcome
primary
barrier,
improve
therapeutic
efficacy,
provide
a
rationale
more
clinical
investigations.
Likewise,
conjugate
or
encapsulate
ICIs,
including
antibodies,
RNAs,
small
molecule
inhibitors.
Therefore,
combining
drug
system
(DDS)
with
could
profitable
immunotherapeutic
treatment.
This
article
reviews
significant
controlled
DDS
current
data
from
pre-clinical
trials
mono-
IMT
limitations.
Graphical
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(13), С. 10859 - 10859
Опубликована: Июнь 29, 2023
The
standard
treatment
of
ovarian
cancer
(OC)
patients,
including
debulking
surgery
and
first-line
chemotherapy,
is
unsatisfactory
because
recurrent
episodes
in
the
majority
(~70%)
patients
with
advanced
OC.
Clinical
trials
have
shown
only
a
modest
(10-15%)
response
OC
individuals
to
based
on
immune
checkpoint
inhibitors
(ICIs).
resistance
therapy
caused
by
various
factors,
heterogeneity,
low
density
tumor-infiltrating
lymphocytes
(TILs),
non-cellular
cellular
interactions
tumor
microenvironment
(TME),
as
well
network
microRNA
regulating
pathways.
Moreover,
ICIs
are
most
efficient
tumors
that
marked
high
microsatellite
instability
mutation
burden,
which
rare
among
patients.
great
challenge
ICI
implementation
connected
distinguishing
hyper-,
pseudo-,
real
progression
disease.
understanding
immunological,
molecular,
genetic
mechanisms
crucial
selecting
group
whom
personalized
would
be
beneficial.
In
this
review,
we
summarize
current
knowledge
about
selected
factors
inducing
discuss
future
directions
ICI-based
immunotherapy
development
for
International Journal of Biological Sciences,
Год журнала:
2024,
Номер
20(10), С. 3911 - 3922
Опубликована: Янв. 1, 2024
Immune
checkpoint
inhibitors
(ICIs)
have
heralded
a
new
era
in
immunotherapy,
representing
pivotal
breakthrough
cancer
treatment.
Their
impact
is
profound,
with
ICIs
standing
as
some
of
the
most
prescribed
anticancer
therapies
today.
Notably,
their
ability
to
induce
long-term
remission
even
after
treatment
cessation
provides
genuine
hope
for
achieving
durable
cures.
However,
despite
these
strides,
challenges
persist
landscape
oncology,
including
resistance
phenomena,
immune-related
adverse
events,
and
suboptimal
response
rates.
In
challenges,
combination
therapy
emerges
promising
approach,
poised
enhance
outcomes
address
limitations
inherent
single-agent
ICI
therapy.
By
synergistically
targeting
multiple
pathways,
holds
potential
augment
therapeutic
efficacy
while
mitigating
toxicity
impeding
emergence
mechanisms.
Understanding
intricacies
underlying
development
events
paramount
devising
novel
refined
strategies.
A
timeline
showing
FDA
approvals
shown
Current Oncology Reports,
Год журнала:
2024,
Номер
26(2), С. 103 - 113
Опубликована: Янв. 2, 2024
In
the
last
decade,
poly
(ADP-ribose)
polymerase
(PARP)
inhibitors
have
been
approved
in
treatment
of
several
cancers,
such
as
breast
and
ovarian
cancer.
This
article
aims
to
discuss
current
uses,
limitations,
future
directions
for
PARP
(PARPis)
Following
results
OlympiAD
EMBRACA
trials,
PARPis
were
HER2-negative
cancer
with
a
germline
BRCA
mutation.
We
reviewed
this
class
drugs'
mechanism
action,
efficacy,
well
further
studies
that
discussed
resistance,
impaired
homologous
recombination
repair
(HRR),
combination
other
drugs.
Improving
understanding
HRR,
increasing
ability
target
combining
novel
agents
are
continuing
increase
clinical
utility
PARPis.
